Category - Markets

BTIG initiated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a “buy” rating and price target of $30. The stock closed at $15.40 on Dec. 6. Akebia is focused on the development of Vadadustat, a novel oral, once...

Leerink initiated coverage of InflaRx N.V. (NASDAQ:IFRX) with an “outperform” rating and $31 price target. The stock closed at $20.88 on Dec. 1. “InflaRx has an opportunity to generate significant shareholder value with...

Roth Capital Partners raised its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $82 from $62 ahead of interim results in late December from the company’s Phase 2b NASH trial. Nonalcoholic steatohepatitis...

Roth Capital Partners launched coverage of Verastem (NASDAQ:VSTM) with a “buy” rating and $12 price target. The stock closed at $3.66 on Nov. 29. Analyst Dr. Jotin Marango writes that his qualitative and quantitative...

Ladenburg Thalmann initiated coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $22 share price target. The stock closed at $8.71 on Nov. 28. Arcturus has developed a novel biodegradable lipid...

Maxim Group raised its price target for Viking Therapeutics (NASDAQ:VKTX) to $8 from $5 after the company announced results of a Phase 2 hip fracture study of its VK5211 compound. The stock was changing hands at $3.07...

Stifel initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and $26 price target. The stock closed at $13.86 on Nov. 24. “We believe Spero’s wholly-owned product pipeline of novel antibiotics –...

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15. Analyst Prakash Gowd...

Leering upgraded Mirati Therapeutics (NASDAQ:MRTX) to “outperform” from “market perform” and raised its price target to $20 from $15, after the company re-prioritized its pipeline programs. The stock closed at $15.50 on...

Stifel initiated coverage of GTx (NASDAQ:GTXI) a “buy” rating and $16 price target. The stock closed at $7.51 on Nov. 8. “We believe the Street is overlooking blockbuster potential for lead pipeline asset, enobosarm, in...